20.54USD+5.77%Mkt Cap: —P/E: —Last update: 2026-06-01
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule fo…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value483.51M USD
Revenue (TTM)63.26M USD
Gross Profit42.34M USD
Net Income (TTM)6.82M USD
Revenue/Share2.267 USD
Last Price20.54 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-7.38
EV/Revenue7.64
P/S—
P/B12.25
EPS (TTM)-0.86
EPS (Forward)—
52W Range
6.27099% of range20.70
52W High20.70 USD
52W Low6.270 USD
Profitability
Gross Margin66.92%
Oper. Margin-29.78%
EBITDA Margin-103.63%
Profit Margin10.77%
ROE13.66%
ROA3.67%
Growth
Revenue Growth6.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.78M USD
CapEx (TTM)—
FCF Margin-74.75%
FCF Yield—
Net Debt-12.16M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity1.49
Current Ratio2.49
Quick Ratio2.20
Book Value/Sh1.590 USD
Cash/Share2.465 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield14.44%
Payout Ratio—
Ex-Div DateJun 14, 2024
Pay DateJun 30, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.56.68M
Float22.38M
Insiders0.00%
Institutions0.00%
Short Interest
Short Ratio0.0d
Shares Short1.04K
Short (prev mo.)298
Technical
SMA 5014.28 (+43.9%)
SMA 20010.59 (+94.0%)
Beta1.16
S&P 52W Chg27.94%
Avg Vol (30d)24.61K
Avg Vol (10d)41.23K
Technical Indicators
RSI (14)87.9
MACD1.3392
MACD Signal0.8459
MACD Hist.+0.4933
BB Upper19.67 USD
BB Middle15.54 USD
BB Lower11.41 USD
BB Width53.12%
ATR (14)0.6620 USD
Vol Ratio (20d)0.95x